1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The interaction of isavuconazole with immunosuppressors (tacrolimus, cyclosporin A, or sirolimus) against 30 Aspergillus isolates belonging to the most common species responsible for invasive aspergillosis in humans ( Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, and Aspergillus terreus) was evaluated in vitro by a microdilution checkerboard technique based on the EUCAST reference method for antifungal susceptibility testing. The interpretation of the results was performed based on the fractional inhibitory concentration index. The combination of isavuconazole with tacrolimus, cyclosporin A, or sirolimus, was synergistic for 56, 20, or 10% of the isolates, respectively. Interestingly synergy of the combination of isavuconazole with tacrolimus was also achieved for the majority of azole-resistant isolates of A. fumigatus, and for all A. niger isolates with isavuconazole minimal inhibitory concentrations ≥ 8 µg/mL. Antagonistic interactions were never observed for any combination tested.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: found

          Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The mechanism of action of cyclosporin A and FK506.

            CsA and FK506 are powerful suppressors of the immune system, most notably of T cells. They act at a point in activation that lies between receptor ligation and the transcription of early genes. Here, Stuart Schreiber and Gerald Crabtree review recent findings that indicate CsA and FK506 operate as prodrugs: they bind endogenous intracellular receptors, the immunophilins, and the resulting complex targets the protein phosphatase, calcineurin, to exert the immunosuppressive effect.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Aspergillosis.

                Bookmark

                Author and article information

                Journal
                J Fungi (Basel)
                J Fungi (Basel)
                jof
                Journal of Fungi
                MDPI
                2309-608X
                08 July 2020
                September 2020
                : 6
                : 3
                : 103
                Affiliations
                [1 ]Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, D-35043 Marburg, Germany
                [2 ]Center for Invasive Mycoses and Antifungals, Philipps University Marburg, D-35037 Marburg, Germany
                [3 ]Dynamyc Research Group (EA 7380), Faculté de Médecine de Créteil, Université Paris-Est-Créteil-Val-de-Marne, F-94010 Créteil, France; eric.dannaoui@ 123456aphp.fr
                [4 ]Unité de Parasitologie-Mycologie, Hôpital Européen Georges-Pompidou, F-75015 Paris, France
                [5 ]Faculté de Médecine, Université de Paris, 75006 Paris, France
                Author notes
                [* ]Correspondence: patrick.schwarz@ 123456med.uni-marburg.de ; Tel.: +49-6421-5862464
                Author information
                https://orcid.org/0000-0003-0383-1865
                https://orcid.org/0000-0002-2817-3830
                Article
                jof-06-00103
                10.3390/jof6030103
                7560155
                32650564
                de97205c-0d96-4775-a64c-c81bafb3ec80
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 17 May 2020
                : 16 June 2020
                Categories
                Article

                antifungal combination,in vitro,aspergillosis,aspergillus,isavuconazole,immunosuppressor,eucast

                Comments

                Comment on this article